The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment

Liver International

Volumn 36, Issue 6, 2016, Pages 791-793

  De Nicola, Stella ^a   Aghemo, Alessio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; SOFOSBUVIR;

ANTIVIRAL THERAPY; ASCITES; CHRONIC HEPATITIS C; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; TREATMENT OUTCOME; HEPACIVIRUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION;

HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84966783713     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13123     Document Type: Editorial

References (19)

1. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 2016; 36(Suppl 1): 47-57.
2. Puoti M, Rossotti R, Baiguera C, Orso M. Treatment of hepatitis C virus genotype 1-infected patients: mission accomplished? Liver Int 2016; 36: 181-4.
3. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
4. Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015; 35: 1923-33.
5. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 2015; 60: 3801-13.
6. Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int 2013; 84: 874-9.
7. Corouge M, Vallet-Pichard A, Pol S. HCV and the kidney. Liver Int 2016; 36(Suppl 1): 28-33.
8. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495-503.
9. Noell BC, Besur SV, deLemos AS. Changing the face of hepatitis C management - the design and development of sofosbuvir. Drug Des Devel Ther 2015; 9: 2367-74.
10. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54.
11. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386: 1537-45.
12. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of Direct-acting Antiviral Combination for Patients with HCV Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology 2016; doi:10.1053/j.gastro.2016.02.078.
13. Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015; 64: 1824-33.
14. Pawlotsky JM. Therapy: Avoiding treatment failures associated with HCV resistance. Nat Rev Gastroenterol Hepatol 2015; 12: 673-4.
15. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with impaired renal function. Liver Int 2016; 36: 807-16.
16. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1- patients with end-stage renal disease on hemodialysis or GFR <30 mL/min. Liver Int 2016; 36: 798-801.
17. Singh T, Guirguis J, Anthony S, et al. Sofosbuvir based treatment is safe and effective in patients with chronic hepatitis C infection and end-stage renal disease: a case series. Liver Int 2016; 36: 802-6.
18. Trakroo S, Sanaka S, Musa H, et al. Treatment of chronic hepatitis c infection in kidney transplant recipients with direct acting antiviral medications - initial experience. Hepatology 2015; 62: S762A.
19. Bhamidimarri KR, Roth D, Guerra G, Levy C, Martin P. Preliminary experience of direct acting antiviral therapy in hepatitis C infected kidney transplant recipients, who received grafts from hepatitis C positive or negative donors. Hepatology 2015; 62: S776A.